Financial Trends News 31 August 2025

Bitcoin vs NYSE 100 vs NASDAQ 100 – 2025’s Epic Market Showdown Reveals Surprising Winner

Late 2025 Conclusion: As of October 10, 2025, Bitcoin, the NYSE 100, and the Nasdaq 100 are all shining – but in different ways. Bitcoin has delivered headline-grabbing returns and captured the imagination of those betting on a new financial paradigm. The Nasdaq-100 has ridden an AI-driven stock boom to new heights, rewarding investors in familiar tech giants. The NYSE’s top 100 firms (and broad market proxies like the S&P 500) have provided solid, steady gains in an economy that proved resilient. For investors asking “which is best?”, the answer lies in their risk appetite and investment horizon. Crypto (Bitcoin)

10 October 2025

Gold $4K vs Bitcoin $125K: Inside the Epic 2025 Safe-Haven Showdown

2025 – A Year of Record Highs for Gold and Bitcoin Gold bars – the classic safe-haven asset – soared to record prices in 2025 as investors worldwide sought stability amid economic storms. Gold’s ascent in 2025 has been nothing short of historic. By October 8, gold broke above $4,000 per ounce for the first time ever, hitting an intraday peak around $4,078 ts2.tech ts2.tech. Just a year or two ago, $4k gold seemed far-fetched, but mounting economic worries turned that milestone into reality. The metal started 2025 near $2,800/oz and then shattered record after record, rising almost 50% in under a year

10 October 2025

Cryptocurrency · Financial Trends · Gold · Investing · Market Analysis · NYSE:BLK

PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

Key Data & Metrics (as of October 9, 2025) Metric Value Stock Price (Oct 8, 2025) $138.84 (close) marketbeat.comDown ~6% in past month; ~–6% YTD finviz.com indexbox.io 52-Week Range Low $127.60 – High $177.48 markets.businessinsider.com Market Capitalization ~$193 Billion markets.businessinsider.com Forward P/E (2025E) ~17.5× (near industry avg ~17.5×) finviz.com Trailing P/E (TTM) ~21.8× markets.businessinsider.com PEG Ratio (Forward) ~3.5 (industry ~2.3) finviz.com Annual Dividend $5.69 per share (yield ~4.0%) macrotrends.net Dividend Growth 53 years consecutive increases (5% hike in 2025) pepsico.com Q3 2025 Revenue $23.94 B (+2.6% YoY) investing.com Q3 2025 Adjusted EPS $2.29 (beat est. $2.26; –1.7% YoY) investing.com finviz.com 2025 Full-Year

9 October 2025

Corporate News · Earnings Reports · Financial Trends · Investment Analysis · NYSE:PEP · Stock Market

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Overview Index Performance The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell, however, Wall Street had staged a dramatic recovery: Contrary to midday reports that the S&P 500 and Nasdaq 100 were modestly negative due to a risk‑off mood nasdaq.com, late‑day buying pushed all major indices into positive territory. Market breadth improved: the S&P 500 recorded 37 new 52‑week highs versus 7 lows, while the Nasdaq tallied 111 highs and 68 lows reuters.com. Sector

1 October 2025

Economic News · Financial Trends · Investment Insights · Market Analysis · NASDAQ:AZN · NASDAQ:BIIB · NYSE:LLY · NYSE:PFE · NYSE:TMO · Stock Market

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder marketbeat.com. It has even explored herbal COVID-19 remedies in the past, though these remain experimental stocktitan.net. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding (largely from its founder) and IPO proceeds. In the

25 September 2025

Biotech News · Company Analysis · Financial Trends · Investing · Stock Market

AI Stocks Whipsaw as Nvidia Stumbles, Alibaba Soars – Key News Aug 30–31, 2025

Wall Street’s AI Rally Hits a Speed Bump After months of euphoria, U.S. equity markets stumbled into the weekend, led by a pullback in AI-focused stocks. On Friday, Aug. 29, the Nasdaq Composite sank about 1.2% and the S&P 500 fell 0.6%, snapping a streak of gains as traders locked in profits on this year’s AI-fueled winners ts2.tech ts2.tech. The sell-off was broad-based: Nvidia slid 3.4% Friday (its third down day in a row), Tesla and Broadcom dropped over 3%, and even mega-caps like Meta, Amazon, Microsoft, and Alphabet gave back 1–2% ts2.tech. High-flying tech names had risen to records

31 August 2025

AI Stocks · Alibaba · Financial Trends · Market News · NASDAQ:AVGO · NASDAQ:MRVL · NASDAQ:NVDA · NVIDIA · NYSE:AI · NYSE:BABA · NYSE:DELL · NYSE:PLTR · Stock Market

Financial Trends News 31 August 2025 - 10 October 2025